35028-38-7

Basic information

• Product Name: Carbamic chloride, cyclohexylmethyl-
• CAS NO: 35028-38-7
• Molecular Formula: C8H14ClNO
• Molecular Weight: 175.658
• Mol File: 35028-38-7.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Carbamic chloride, cyclohexylmethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic chloride, cyclohexylmethyl-(35028-38-7)
• EPA Substance Registry System: Carbamic chloride, cyclohexylmethyl-(35028-38-7)

Safety Data

• Hazardous Substances Data: 35028-38-7(Hazardous Substances Data)

Upstream product

• 100-60-7 N-methylcyclohexylamine 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 75-44-5 phosgene 

Downstream Products

• 68721-98-2 Cyclohexyl-methyl-carbamic acid 2,5-dimethyl-4-methylsulfanyl-phenyl ester 
• 1233855-46-3 3-(1-(cyclohexyl(methyl)carbamoyl)-1H-imidazol-4-yl)pyridine 1-oxide 
• 1233852-83-9 N-cyclohexyl-N-methyl-4-phenyl-1H-imidazole-1-carboxamide 
• 1548620-14-9 N-cyclohexyl-N-methylpiperidine-1-carboxamide 
• 1548620-11-6 1-benzyl-3-cyclohexyl-1,3-dimethylurea 
• 1548620-08-1 N-cyclohexyl-4-(3,5-dinitrophenyl)-N-methyl-1H-imidazole-1-carboxamide 
• 1233855-25-8 N-cyclohexyl-4-(4-methoxyphenyl)-N-methyl-1H-imidazole-1-carboxamide 
• 1233855-18-9 N-cyclohexyl-N-methyl-4-(pyridin-3-yl)-1H-imidazole-1-carboxamide 
• 1443159-47-4 5-(biphenyl-4-ylmethyl)-N-cyclohexyl-N-methyl-1H-tetrazole-1-carboxamide 
• 1443159-51-0 5-(biphenyl-4-ylmethyl)-N-cyclohexyl-N-methyl-2H-tetrazole-2-carboxamide 
• 1207262-57-4 2-(5-{4-[cyclohexy(methyl)carbamoyl]piperazin-1-yl}-1,2,4-oxadiazol-3-yl)-1-methyl-1H-3,1-benzimidazol-3-ium trifluoroacetate 
• 209394-74-1 cyclohexyl-methyl-carbamic acid 3-tert-butoxycarbonylamino-indan-5-yl ester 
• 1026305-82-7 cyclohexyl-methyl-carbamic acid 3-(2-tert-butoxycarbonylamino-propyl)-phenyl ester 

Relevant articles and documents

Design, synthesis and anti-inflammatory effects of novel 9-O-substituted-berberine derivatives

Berberine, an isoquinoline alkaloid in many medicinal herbs, has been found to possess broad pharmacological activities. A series of novel C-9-O-substituted-berberine derivatives have been synthesized and their anti-inflammatory effects evaluated both in vitro and in vivo. Compared to berberine, the new synthetic berberine derivatives 3i and 5e exhibit significantly improved inhibitory activities against the release of NO, TNF-α and IL-6. Furthermore, derivatives 3i and 5e were found to inhibit more effectively the migration of neutrophils and primitive macrophage in transgenic zebrafish larvae with injury-provoked inflammation. Pre-treatment with derivatives 3i or 5e could lead to a concentration-dependent decrease in nuclear factor-κB (NF-κB) p65 and NF-κB inhibitor α (IκBα) phosphorylation and inducible nitric oxide synthase (iNOS) expression in lipopolysaccharide (LPS)-induced RAW264.7 cells, which suggested that the anti-inflammatory activities of berberine derivatives 3i and 5e are related to their suppression of the NF-κB signal pathway.

PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS

A process for preparing a substituted urea compound of Formula II or Formula I, or a pharmaceutically acceptable salt or ester thereof, Formula II, Formula I the process comprising the reaction of an intermediate of Formula II' or Formula 1', Formula II',

1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts, stereoisomers or tautomers thereof which are inhibitors of the Sonic Hedgehog pathway, in particular Smo antagonists. Thus the compounds of this invention are useful for the treatment of diseases associated with abnormal hedgehog pathway activation, including cancer, for example basal cell carcinoma, medulloblastoma, prostate, pancreatic, breast, colon, bone and small cell lung cancers, and cancers of the upper GI tract.